CytoReason, an Israeli firm that leverages machine learning tech for drug discovery and development, announced that it has entered into a collaboration agreement with US-based pharmaceutical multinational Pfizer.
Founded in 2016, the company’s proprietary platform combines scientific and experimental data for immune system simulations applicable to cancer immunotherapy, and autoimmune, neurodegenerative and infectious disease research. The startup’s technology has yielded two pending patents and 10 commercial and scientific collaborations, it says
“We believe that CytoReason’s platform has the potential to offer valuable insights that may be applied to our research into the human immune system,” said Michael Vincent, Chief Scientific Officer, Inflammation & Immunology, Pfizer. “Leveraging technologies such as this can help us understand disease and prioritize targets, and support our mission of bringing innovative new therapies to patients who need them.”
“The collaboration with Pfizer will further strengthen our models in our core therapeutic areas. This will be our fifth major partnership, which we believe will help make our model unparalleled in its accuracy for assets across the pipeline,” said CytoReason CEO David Harel. “CytoReason’s model brings together thousands of samples on a cell-protein-gene level, allowing for fast and accurate insights.”